Marina Baretti

I am a clinical translational researcher in gastrointestinal (GI) oncology, collaborating closely with laboratory-based researchers to move laboratory findings into patients and to answer important clinical questions.

Baltimore, Maryland, United States of America

About

Throughout my training, I have been focused toward my ultimate goal of becoming a clinical translational researcher in gastrointestinal (GI) oncology, collaborating closely with laboratory-based researchers to move laboratory findings into patients and to answer important clinical questions. My clinical research is centered on the development of novel agents in GI cancers, with particular interest in combinatorial approaches of epigenetic therapies and immunotherapies combinations. I ran the first phase II study of combination epigenetic therapy and immunotherapy in advanced pancreatic adenocarcinoma and cholangiocarcinoma, working with a collaborative team that incorporates leading experts in cancer immunology, epigenetics and drug development. I was awarded the 2018 ASCO Conquer Cancer Foundation Young Investigator Award for this project.  Together with Dr. Yarchoan, we are running a clinical trial of a novel neoantigen-specific vaccine in combination with immune checkpoint inhibitors for advanced fibrolamellar carcinoma (FLC) (NCT04248569). My laboratory focus has been on developing and validating a preclinical mouse model of FLC to investigate mechanisms underlying FLC pathogenesis, and will become a critical tool for investigating novel therapeutic strategies in FLC.

Experience

Johns Hopkins University

Co-Director of the Liver and Biliary Cancer Multidisciplinary Clinic at Johns Hopkins, Baltimore, MD / January, 2023Present

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins School of Medicine, Baltimore, MD

Assistant professor / October, 2021Present

Publications

DNA mismatch repair in cancer

Pharmacology & Therapeutics / Sep 01, 2018

Baretti, M., & Le, D. T. (2018). DNA mismatch repair in cancer. Pharmacology & Therapeutics, 189, 45–62. https://doi.org/10.1016/j.pharmthera.2018.04.004

An analysis of genetic heterogeneity in untreated cancers

Nature Reviews Cancer / Aug 27, 2019

Reiter, J. G., Baretti, M., Gerold, J. M., Makohon-Moore, A. P., Daud, A., Iacobuzio-Donahue, C. A., Azad, N. S., Kinzler, K. W., Nowak, M. A., & Vogelstein, B. (2019). An analysis of genetic heterogeneity in untreated cancers. Nature Reviews Cancer, 19(11), 639–650. https://doi.org/10.1038/s41568-019-0185-x

Neutrophil and lymphocyte blood count as potential predictive indicators of nivolumab efficacy in metastatic non-small-cell lung cancer

Immunotherapy / Jul 01, 2020

Rossi, S., Toschi, L., Finocchiaro, G., & Santoro, A. (2020). Neutrophil and lymphocyte blood count as potential predictive indicators of nivolumab efficacy in metastatic non-small-cell lung cancer. Immunotherapy, 12(10), 715–724. https://doi.org/10.2217/imt-2019-0154

Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer

Digestive and Liver Disease / Oct 01, 2015

Sefrioui, D., Sarafan-Vasseur, N., Beaussire, L., Baretti, M., Gangloff, A., Blanchard, F., Clatot, F., Sabourin, J.-C., Sesboüé, R., Frebourg, T., Michel, P., & Di Fiore, F. (2015). Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer. Digestive and Liver Disease, 47(10), 884–890. https://doi.org/10.1016/j.dld.2015.05.023

The role of epigenetic therapies in colorectal cancer

Current Problems in Cancer / Nov 01, 2018

Baretti, M., & Azad, N. S. (2018). The role of epigenetic therapies in colorectal cancer. Current Problems in Cancer, 42(6), 530–547. https://doi.org/10.1016/j.currproblcancer.2018.03.001

Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram

Annals of Oncology / Mar 01, 2017

Pietrantonio, F., Miceli, R., Rimassa, L., Lonardi, S., Aprile, G., Mennitto, A., Marmorino, F., Bozzarelli, S., Antonuzzo, L., Tamburini, E., Morano, F., Rossini, D., Battaglin, F., Baretti, M., Berenato, R., Formica, V., Mosconi, S., Petrelli, F., Ghidini, M., … Cremolini, C. (2017). Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. Annals of Oncology, 28(3), 555–561. https://doi.org/10.1093/annonc/mdw627

KRAS mutation in lung metastases from colorectal cancer: prognostic implications

Cancer Medicine / Dec 29, 2015

Ghidini, M., Personeni, N., Bozzarelli, S., Baretti, M., Basso, G., Bianchi, P., Tronconi, M. C., Pressiani, T., Grizzi, F., Giordano, L., Malesci, A., Alloisio, M., Laghi, L., Santoro, A., & Rimassa, L. (2015). <scp>KRAS</scp> mutation in lung metastases from colorectal cancer: prognostic implications. Cancer Medicine, 5(2), 256–264. Portico. https://doi.org/10.1002/cam4.592

Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma

Immunotherapy / Dec 01, 2016

Simonelli, M., Di Tommaso, L., Baretti, M., & Santoro, A. (2016). Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma. Immunotherapy, 8(12), 1363–1369. https://doi.org/10.2217/imt-2016-0057

Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures

JCO Precision Oncology / Jun 01, 2022

Mody, K., Jain, P., El-Refai, S. M., Azad, N. S., Zabransky, D. J., Baretti, M., Shroff, R. T., Kelley, R. K., El-Khouiery, A. B., Hockenberry, A. J., Lau, D., Lesinski, G. B., & Yarchoan, M. (2022). Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures. JCO Precision Oncology, 6. https://doi.org/10.1200/po.21.00510

Epigenetic modifiers synergize with immune-checkpoint blockade to enhance long-lasting antitumor efficacy

Journal of Clinical Investigation / Aug 16, 2021

Baretti, M., & Yarchoan, M. (2021). Epigenetic modifiers synergize with immune-checkpoint blockade to enhance long-lasting antitumor efficacy. Journal of Clinical Investigation, 131(16). https://doi.org/10.1172/jci151002

Targeting the epigenome of pancreatic cancer for therapy: challenges and opportunities

Annals of Pancreatic Cancer / Oct 01, 2019

Baretti, M., Ahuja, N., & Azad, N. S. (2019). Targeting the epigenome of pancreatic cancer for therapy: challenges and opportunities. Annals of Pancreatic Cancer, 2, 18–18. https://doi.org/10.21037/apc.2019.10.01

Prognostic Implications of the Immune Tumor Microenvironment in Patients With Pancreatic and Gastrointestinal Neuroendocrine Tumors

Pancreas / May 01, 2021

Baretti, M., Zhu, Q., Zahurak, M., Bhaijee, F., Xu, H., Engle, E. L., Kotte, A., Pawlik, T. M., Anders, R. A., & De Jesus-Acosta, A. (2021). Prognostic Implications of the Immune Tumor Microenvironment in Patients With Pancreatic and Gastrointestinal Neuroendocrine Tumors. Pancreas, 50(5), 719–726. https://doi.org/10.1097/mpa.0000000000001831

Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma and pancreatic adenocarcinoma.

Journal of Clinical Oncology / May 20, 2018

Baretti, M., Durham, J. N., Walker, R., Mitcheltree, A.-L., Christmas, B., Cope, L., Jaffee, E. M., & Azad, N. S. (2018). Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma and pancreatic adenocarcinoma. Journal of Clinical Oncology, 36(15_suppl), TPS4151–TPS4151. https://doi.org/10.1200/jco.2018.36.15_suppl.tps4151

Surgical Debulking for Refractory Hyperammonemic Encephalopathy in Fibrolamellar Hepatocellular Carcinoma

Hepatology / Aug 21, 2021

Solipuram, V., Baretti, M., Kim, A. Y., Chen, L. X., Fahrner, J. A., Gunay‐Aygun, M., Peng, X. P., Hardenbergh, D., Ferguson, A., Griffith, P., Wang, Y., Brancati, M., Gopalakrishna, H., Kato, T., Shubert, C., Laheru, D., & Yarchoan, M. (2021). Surgical Debulking for Refractory Hyperammonemic Encephalopathy in Fibrolamellar Hepatocellular Carcinoma. Hepatology, 74(5), 2899–2901. https://doi.org/10.1002/hep.31998

Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic

Cancer Control / Jan 01, 2021

Jia, A. Y., Popovic, A., Mohan, A. A., Zorzi, J., Griffith, P., Kim, A. K., Anders, R. A., Burkhart, R. A., Lafaro, K., Georgiades, C., Azad, N. S., Liddell, R. P., Baretti, M., Kamel, I. R., Narang, A., Yarchoan, M., & Meyer, J. (2021). Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic. Cancer Control, 28, 107327482110099. https://doi.org/10.1177/10732748211009945

Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection

OncoImmunology / Jan 01, 2021

Delitto, D., Zabransky, D. J., Chen, F., Thompson, E. D., Zimmerman, J. W., Armstrong, T. D., Leatherman, J. M., Suri, R., Lopez-Vidal, T. Y., Huff, A. L., Lyman, M. R., Guinn, S. R., Baretti, M., Kagohara, L. T., Ho, W. J., Azad, N. S., Burns, W. R., He, J., Wolfgang, C. L., … Jaffee, E. M. (2021). Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. OncoImmunology, 10(1). https://doi.org/10.1080/2162402x.2021.2001159

Expanding the immunotherapy roadmap for hepatocellular carcinoma

Cancer Cell / Mar 01, 2022

Baretti, M., Kim, A. K., & Anders, R. A. (2022). Expanding the immunotherapy roadmap for hepatocellular carcinoma. Cancer Cell, 40(3), 252–254. https://doi.org/10.1016/j.ccell.2022.02.017

A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype

Clinical and Translational Science / Apr 03, 2021

Baretti, M., Karunasena, E., Zahurak, M., Walker, R., Zhao, Y., Pisanic, T. R., Wang, T., Greten, T. F., Duffy, A. G., Gootjes, E., Meijer, G., Verheul, H. M. W., Ahuja, N., Herman, J. G., & Azad, N. S. (2021). A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype. Clinical and Translational Science, 14(3), 954–963. Portico. https://doi.org/10.1111/cts.12960

Precision Cancer Trials With Immunomodulatory Agents

The Cancer Journal / Jul 01, 2019

Baretti, M., & Azad, N. S. (2019). Precision Cancer Trials With Immunomodulatory Agents. The Cancer Journal, 25(4), 287–295. https://doi.org/10.1097/ppo.0000000000000390

Regorafenib in patients with refractory metastatic pancreatic cancer. An open-label phase II study (RESOUND)

Annals of Oncology / Oct 01, 2016

Bozzarelli, S., Rimassa, L., Giordano, L., Sala, S., Tronconi, M. C., Baretti, M., Personeni, N., Pressiani, T., & Santoro, A. (2016). Regorafenib in patients with refractory metastatic pancreatic cancer. An open-label phase II study (RESOUND). Annals of Oncology, 27, vi233. https://doi.org/10.1093/annonc/mdw371.84

Clinical Interest of Digital Pcr for Routine Detection of Circulating Dna in Metastatic Colorectal Cancer

Annals of Oncology / Sep 01, 2014

Sefrioui, D., Vasseur, C., Sesboué, R., Blanchard, F., Gangloff, A., Baretti, M., Beaussire, L., Clatot, F., Dolfus, C., Sabourin, J., Michel, P., Frebourg, T., & Di Fiore, F. (2014). Clinical Interest of Digital Pcr for Routine Detection of Circulating Dna in Metastatic Colorectal Cancer. Annals of Oncology, 25, iv559. https://doi.org/10.1093/annonc/mdu358.48

Modified Folfoxiri in advanced Pancreatic Cancer

Annals of Oncology / Sep 01, 2012

Ginocchi, L., Vasile, E., Caponi, S., Lucchesi, M., Caparello, C., Da Prat, V., Baretti, M., Lencioni, M., Ricci, S., & Falcone, A. (2012). Modified Folfoxiri in advanced Pancreatic Cancer. Annals of Oncology, 23, ix238. https://doi.org/10.1016/s0923-7534(20)33292-0

TH-302 + Gemcitabine (G + T) vs Gemcitabine (G) in Patients with Previously Untreated advanced Pancreatic Cancer (PAC)

Annals of Oncology / Sep 01, 2012

Borad, M., Reddy, S., Bahary, N., Uronis, H., Sigal, D. S., Cohn, A. L., Schelman, W., Stephenson, J., Eng, C., & Ryan, D. P. (2012). TH-302 + Gemcitabine (G + T) vs Gemcitabine (G) in Patients with Previously Untreated advanced Pancreatic Cancer (PAC). Annals of Oncology, 23, ix224. https://doi.org/10.1093/annonc/mds398

Impact of the COVID-19 Pandemic on Liver Cancer Staging at a Multidisciplinary Liver Cancer Clinic

Annals of Surgery Open / Oct 03, 2022

Li, D., Jia, A. Y., Zorzi, J., Griffith, P., Kim, A. K., Dao, D., Anders, R. A., Georgiades, C., Liddell, R. P., Hong, K., Azad, N. S., Ho, W. J., Baretti, M., Christenson, E., Baghdadi, A., Kamel, I. R., Meyer, J., Ghabi, E., Burkhart, R. A., … Yarchoan, M. (2022). Impact of the COVID-19 Pandemic on Liver Cancer Staging at a Multidisciplinary Liver Cancer Clinic. Annals of Surgery Open, 3(4), e207. https://doi.org/10.1097/as9.0000000000000207

Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors

Cancers / Oct 30, 2022

Chen, K. Y., Popovic, A., Hsiehchen, D., Baretti, M., Griffith, P., Bista, R., Baghdadi, A., Kamel, I. R., Simon, S. M., Migler, R. D., & Yarchoan, M. (2022). Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers, 14(21), 5347. https://doi.org/10.3390/cancers14215347

1470P Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence

Annals of Oncology / Sep 01, 2021

Heumann, T. R., Baretti, M., Sugar, E., Durhman, J., Liden, S., Miles, T., Lopez-Vidal, T. Y., Leatherman, J., Sharma, A., Ahuja, N., Weekes, C. D., O’Dwyer, P. J., Monga, D. K., Reiss Binder, K. A., & Azad, N. (2021). 1470P Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Annals of Oncology, 32, S1087–S1088. https://doi.org/10.1016/j.annonc.2021.08.797

Successful Treatment With Scrambler Therapy for Radial and Femoral Nerve Injuries After Extracorporeal Membrane Oxygenation

Mayo Clinic Proceedings / May 01, 2021

Smith, T. J., Ferguson, A., Baretti, M., & Yarchoan, M. (2021). Successful Treatment With Scrambler Therapy for Radial and Femoral Nerve Injuries After Extracorporeal Membrane Oxygenation. Mayo Clinic Proceedings, 96(5), 1374–1375. https://doi.org/10.1016/j.mayocp.2021.03.025

AB049. P-17. A phase II study of HDAC inhibition to sensitize to immunotherapy in advanced cholangiocarcinoma

HepatoBiliary Surgery and Nutrition / Mar 01, 2019

Baretti, M., Walker, R., Durham, J., Christmas, B., Cope, L., Jaffee, E. M., & Azad, N. S. (2019). AB049. P-17. A phase II study of HDAC inhibition to sensitize to immunotherapy in advanced cholangiocarcinoma. HepatoBiliary Surgery and Nutrition, 8(S1), AB049–AB049. https://doi.org/10.21037/hbsn.2019.ab049

Estimating 12-weeks life expectancy in metastatic gastric cancer (mGC) patients (pts) candidates for second-line treatment: The “Gastric Life” nomogram

Annals of Oncology / Sep 01, 2017

Pietrantonio, F., Barretta, F., Fanotto, V., Niger, M., Morano, F., Bergamo, F., Silvestris, N., Fornaro, L., Bordonaro, R., Baretti, M., Santini, D., Tomasello, G., Antonuzzo, L., Noventa, S., Avallone, A., Di Donato, S., Maiello, E., De Vita, F., Miceli, R., & Aprile, G. (2017). Estimating 12-weeks life expectancy in metastatic gastric cancer (mGC) patients (pts) candidates for second-line treatment: The “Gastric Life” nomogram. Annals of Oncology, 28, v227. https://doi.org/10.1093/annonc/mdx369.052

ONC-2014-001: An open-label phase II study of regorafenib in patients with metastatic solid tumors who have progressed after standard therapy - RESOUND

Annals of Oncology / Oct 01, 2015

Bozzarelli, S., Rimassa, L., Giordano, L., Garassino, I., Marrari, A., Tronconi, M. C., De Sanctis, R. M., Cavina, R., Baretti, M., Personeni, N., Pressiani, T., & Santoro, A. (2015). ONC-2014-001: An open-label phase II study of regorafenib in patients with metastatic solid tumors who have progressed after standard therapy - RESOUND. Annals of Oncology, 26, vi150. https://doi.org/10.1093/annonc/mdv348.59

Abstract 3679: DNAJB1-PRKACA fusion in fibrolamellar hepatocellular carcinoma induces glutamine addiction and an immunosuppressive tumor microenvironment

Cancer Research / Apr 04, 2023

Kamdar, Z., Lopez-Vidal, T., Howe, K., Munjal, K., Saeed, A., Zabransky, D., Shu, D., Longway, G., Kartalia, E., Leatherman, J., Mohan, A., Khare, P., Zhang, C., Le, A., Pearce, E., Furth, M., Baretti, M., Leone, R., Jaffee, E., & Yarchoan, M. (2023). Abstract 3679: DNAJB1-PRKACA fusion in fibrolamellar hepatocellular carcinoma induces glutamine addiction and an immunosuppressive tumor microenvironment. Cancer Research, 83(7_Supplement), 3679–3679. https://doi.org/10.1158/1538-7445.am2023-3679

A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence

Clinical Epigenetics / Dec 01, 2022

Heumann, T. R., Baretti, M., Sugar, E. A., Durham, J. N., Linden, S., Lopez-Vidal, T. Y., Leatherman, J., Cope, L., Sharma, A., Weekes, C. D., O’Dwyer, P. J., Reiss, K. A., Monga, D. K., Ahuja, N., & Azad, N. S. (2022). A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Clinical Epigenetics, 14(1). https://doi.org/10.1186/s13148-022-01367-8

Epigenetic therapy and DNA damage response

Epigenetics and DNA Damage / Jan 01, 2022

Baretti, M., & Azad, N. S. (2022). Epigenetic therapy and DNA damage response. Epigenetics and DNA Damage, 227–252. https://doi.org/10.1016/b978-0-323-91081-1.00009-1

Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer

Oncotarget / Jul 28, 2022

Baretti, M., Zhu, Q., Fu, W., Meyer, J., Wang, H., Anders, R. A., & Azad, N. S. (2022). Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer. Oncotarget, 13(1), 907–917. https://doi.org/10.18632/oncotarget.28255

SILVELUL project: Immunohistochemical panel analyses as potential predictive and prognostic factors in pancreatic neuroendocrine tumours (PanNET) treated with CAPTEM or everolimus

Annals of Oncology / Oct 01, 2019

De Jesus-Acosta, A., Crespo Herrero, G., Gómez-Dorronsoro, M. L., Alonso, V., Riesco Martinez, M. C., Custodio, A., Lopez, C., Benavent, M., Carmona Bayonas, A., Jimenez-Fonseca, P., Llanos, M., López De San Vicente, B., Arrazubi Arrula, V., Grandez, R., González-Borja, I., Goñi, S., Arozarena, I., Baretti, M., & Viudez, A. (2019). SILVELUL project: Immunohistochemical panel analyses as potential predictive and prognostic factors in pancreatic neuroendocrine tumours (PanNET) treated with CAPTEM or everolimus. Annals of Oncology, 30, v196. https://doi.org/10.1093/annonc/mdz245.006

Chemoradiation-induced alteration of programmed death-ligand 1 and CD8+ tumor-infiltrating lymphocytes in rectal cancer.

Journal of Clinical Oncology / Feb 01, 2019

Baretti, M., Fu, W., Wang, H., Anders, R. A., Azad, N. S., & Zhu, Q. (2019). Chemoradiation-induced alteration of programmed death-ligand 1 and CD8+ tumor-infiltrating lymphocytes in rectal cancer. Journal of Clinical Oncology, 37(4_suppl), 570–570. https://doi.org/10.1200/jco.2019.37.4_suppl.570

The impact of the immune microenvironment in patients with GEP-NETs.

Journal of Clinical Oncology / Feb 01, 2019

Baretti, M., Zhu, Q., Zahurak, M., Pawlik, T. M., Anders, R. A., & De Jesus-Acosta, A. (2019). The impact of the immune microenvironment in patients with GEP-NETs. Journal of Clinical Oncology, 37(4_suppl), 267–267. https://doi.org/10.1200/jco.2019.37.4_suppl.267

Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram

Annals of Oncology / Oct 01, 2017

Morano, F., Pietrantonio, F., Barretta, F., Fanotto, V., Niger, M., Nichetti, F., Bergamo, F., Silvestris, N., Fornaro, L., Bordonaro, R., Baretti, M., Santini, D., Tomasello, G., Antonuzzo, L., Noventa, S., Avallone, A., Di Donato, S., Maiello, E., De Vita, F., & Aprile, G. (2017). Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram. Annals of Oncology, 28, vi46–vi47. https://doi.org/10.1093/annonc/mdx425.008

Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram

Annals of Oncology / Oct 01, 2017

Morano, F., Pietrantonio, F., Barretta, F., Fanotto, V., Niger, M., Nichetti, F., Bergamo, F., Silvestris, N., Fornaro, L., Bordonaro, R., Baretti, M., Santini, D., Tomasello, G., Antonuzzo, L., Noventa, S., Avallone, A., Di Donato, S., Maiello, E., De Vita, F., & Aprile, G. (2017). Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram. Annals of Oncology, 28, vi46–vi47. https://doi.org/10.1093/annonc/mdx425.008

P1.07-018 Incidence of Brain Recurrence and Survival Outcomes in High-Grade Neuroendocrine Carcinomas of the Lung: Implications for Clinical Practice

Journal of Thoracic Oncology / Jan 01, 2017

Mountzios, G., Ricciuti, B., Chiari, R., Baretti, M., Falcinelli, L., Giannarelli, D., Sidoni, A., Crinò, L., Bellezza, G., Rebonato, A., Ferolla, P., Toschi, L., & Metro, G. (2017). P1.07-018 Incidence of Brain Recurrence and Survival Outcomes in High-Grade Neuroendocrine Carcinomas of the Lung: Implications for Clinical Practice. Journal of Thoracic Oncology, 12(1), S706–S707. https://doi.org/10.1016/j.jtho.2016.11.930

Evaluation of Charlson comorbidity index as predictor of survival in stage II-III colorectal cancer patients treated with surgery and neoadjuvant/adjuvant chemotherapy: A single Institution observational study

Annals of Oncology / Oct 01, 2016

Baretti, M., Personeni, N., Giordano, L., Tronconi, M. C., Pressiani, T., Bozzarelli, S., Rimassa, L., & Santoro, A. (2016). Evaluation of Charlson comorbidity index as predictor of survival in stage II-III colorectal cancer patients treated with surgery and neoadjuvant/adjuvant chemotherapy: A single Institution observational study. Annals of Oncology, 27, vi183. https://doi.org/10.1093/annonc/mdw370.104

Prognostic impact of comorbidity in stage II-III colorectal cancer (CRC) patients treated with surgery and neoadjuvant/adjuvant chemotherapy: a single Institution observational study

Annals of Oncology / Sep 01, 2016

Baretti, M., Giordano, L., Rimassa, L., Tronconi, M. C., Pressiani, T., Bozzarelli, S., Personeni, N., & Santoro, A. (2016). Prognostic impact of comorbidity in stage II-III colorectal cancer (CRC) patients treated with surgery and neoadjuvant/adjuvant chemotherapy: a single Institution observational study. Annals of Oncology, 27, iv48. https://doi.org/10.1093/annonc/mdw335.29

An open-label phase II study (RESOUND) of Regorafenib in patients with refractory solid tumors. Results of pancreatic cohort

Annals of Oncology / Sep 01, 2016

Bozzarelli, S., Rimassa, L., Giordano, L., Sala, S., Tronconi, M. C., Baretti, M., Personeni, N., Pressiani, T., & Santoro, A. (2016). An open-label phase II study (RESOUND) of Regorafenib in patients with refractory solid tumors. Results of pancreatic cohort. Annals of Oncology, 27, iv25. https://doi.org/10.1093/annonc/mdw333.29

Palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer: a large Italian experience

Annals of Oncology / Sep 01, 2016

Fanotto, V., Fontanella, C., Cordio, S., Pasquini, G., Baretti, M., Filippi, R., Rosati, G., Santini, D., Giampieri, R., Di Donato, S., Tomasello, G., Brunetti, O., Caporale, M., Bergamo, F., Avallone, A., Scartozzi, M., Lutrino, E. S., Melisi, D., Antonuzzo, L., … Aprile, G. (2016). Palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer: a large Italian experience. Annals of Oncology, 27, iv18. https://doi.org/10.1093/annonc/mdw333.03

P-173 Outcomes of palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer

Annals of Oncology / Jun 01, 2016

Fanotto, V., Fontanella, C., Cordio, S., Pasquini, G., Baretti, M., Filippi, R., Rosati, G., Santini, D., Giampieri, R., Di Donato, S., Tomasello, G., Brunetti, O., Caporale, M., Bergamo, F., Avallone, A., Scartozzi, M., Lutrino, S., Melisi, D., Antonuzzo, L., … Aprile, G. (2016). P-173 Outcomes of palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer. Annals of Oncology, 27, ii51. https://doi.org/10.1093/annonc/mdw199.167

O-013 A new nomogram for estimating 12-weeks survival in patients (pts) with chemorefractory metastatic colorectal cancer (mCRC)

Annals of Oncology / Jun 01, 2016

Pietrantonio, F., Cremolini, C., Rimassa, L., Lonardi, S., Mennitto, A., Morano, F., Iacono, D., Berenato, R., Caporale, M., Niger, M., Marmorino, F., Bozzarelli, S., Bergamo, F., Rossini, D., Baretti, M., Battaglin, F., Bonotto, M., Loupakis, F., de Braud, F., & Miceli, R. (2016). O-013 A new nomogram for estimating 12-weeks survival in patients (pts) with chemorefractory metastatic colorectal cancer (mCRC). Annals of Oncology, 27, ii122. https://doi.org/10.1093/annonc/mdw198.13

L’esperienza italo-brasiliana nell'uso della mediazione in risposta alla crisi del monopolio statale di soluzione di conflitti e la garanzia di acceso alla giustizia

Revista de Direitos e Garantias Fundamentais / Aug 06, 2012

Pinho, H. D. B. de, & Paumgartten, M. P. (2012). L’esperienza italo-brasiliana nell’uso della mediazione in risposta alla crisi del monopolio statale di soluzione di conflitti e la garanzia di acceso alla giustizia. Revista de Direitos e Garantias Fundamentais, 11, 171. https://doi.org/10.18759/rdgf.v0i11.178

Third-Line Folfiri in Metastatic Gastric Cancer Patients

Annals of Oncology / Sep 01, 2012

Caparello, C., Vasile, E., Lencioni, M., Fabrini, M. G., Lucchesi, M., Ginocchi, L., Caponi, S., Santi, S., Ricci, S., & Falcone, A. (2012). Third-Line Folfiri in Metastatic Gastric Cancer Patients. Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33344-5

Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC)

Annals of Oncology / Sep 01, 2012

Caparello, C., Lencioni, M., Vasile, E., Caponi, S., Santi, S., Fabrini, M. G., Ginocchi, L., Lucchesi, M., Ricci, S., & Falcone, A. (2012). Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC). Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33343-3

Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC)

Annals of Oncology / Sep 01, 2012

Caparello, C., Lencioni, M., Vasile, E., Caponi, S., Santi, S., Fabrini, M. G., Ginocchi, L., Lucchesi, M., Ricci, S., & Falcone, A. (2012). Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC). Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33343-3

Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC)

Annals of Oncology / Sep 01, 2012

Caparello, C., Lencioni, M., Vasile, E., Caponi, S., Santi, S., Fabrini, M. G., Ginocchi, L., Lucchesi, M., Ricci, S., & Falcone, A. (2012). Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC). Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33343-3

Evaluation of prognostic factors and of the role of adjuvant chemotherapy in patients with invasive carcinoma derived from intraductal papillary mucinous neoplasms (IPMNs) of the pancreas.

Journal of Clinical Oncology / May 20, 2010

Vasile, E., Caponi, S., Lucchesi, M., Del Chiaro, M., Funel, N., Ginocchi, L., Campani, D., Falcone, A., Boggi, U., & Mosca, F. (2010). Evaluation of prognostic factors and of the role of adjuvant chemotherapy in patients with invasive carcinoma derived from intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. Journal of Clinical Oncology, 28(15_suppl), e14605–e14605. https://doi.org/10.1200/jco.2010.28.15_suppl.e14605

The Significance of Ascites in Patients With Pancreatic Ductal Adenocarcinoma

Pancreas / Apr 01, 2019

Baretti, M., Pulluri, B., Tsai, H.-L., Blackford, A. L., Wolfgang, C. L., Laheru, D., Zheng, L., Herman, J., Le, D. T., Narang, A. K., & de Jesus-Acosta, A. (2019). The Significance of Ascites in Patients With Pancreatic Ductal Adenocarcinoma. Pancreas, 48(4), 585–589. https://doi.org/10.1097/mpa.0000000000001262

Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study

Clinical Colorectal Cancer / Sep 01, 2018

Baretti, M., Rimassa, L., Personeni, N., Giordano, L., Tronconi, M. C., Pressiani, T., Bozzarelli, S., & Santoro, A. (2018). Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study. Clinical Colorectal Cancer, 17(3), e489–e498. https://doi.org/10.1016/j.clcc.2018.03.010

Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?

Cancer Biology & Therapy / Apr 13, 2018

Baretti, M., Personeni, N., Destro, A., Santoro, A., & Rimassa, L. (2018). Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity? Cancer Biology &amp; Therapy, 19(8), 659–663. https://doi.org/10.1080/15384047.2018.1450117

Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications

Gastric Cancer / Aug 16, 2016

Personeni, N., Baretti, M., Bozzarelli, S., Spaggiari, P., Rubino, L., Tronconi, M. C., Fumagalli Romario, U., Rosati, R., Giordano, L., Roncalli, M., Santoro, A., & Rimassa, L. (2016). Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. Gastric Cancer, 20(3), 428–437. https://doi.org/10.1007/s10120-016-0625-1

Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice

Lung Cancer / May 01, 2016

Metro, G., Ricciuti, B., Chiari, R., Baretti, M., Falcinelli, L., Giannarelli, D., Sidoni, A., Mountzios, G., Crinò, L., Bellezza, G., Rebonato, A., Ferolla, P., & Toschi, L. (2016). Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice. Lung Cancer, 95, 82–87. https://doi.org/10.1016/j.lungcan.2016.03.006

Research Interests

Oncology
Pharmacology (medical)
Pharmacology
Hematology
Gastroenterology
Hepatology
Cancer Research
Immunology
Immunology and Allergy
Radiology, Nuclear Medicine and imaging
Internal Medicine
Molecular Medicine
General Medicine
Genetics (clinical)
Genetics
Molecular Biology
Join Marina on NotedSource!

At NotedSource, we believe that professors, post-docs, scientists and other researchers have deep, untapped knowledge and expertise that can be leveraged to drive innovation within companies. NotedSource is committed to bridging the gap between academia and industry by providing a platform for collaboration with industry and networking with other researchers.

For industry, NotedSource identifies the right academic experts in 24 hours to help organizations build and grow. With a platform of thousands of knowledgeable PhDs, scientists, and industry experts, NotedSource makes connecting and collaborating easy.

For academic researchers such as professors, post-docs, and Ph.D.s, NotedSource provides tools to discover and connect to your colleagues with messaging and news feeds, in addition to the opportunity to be paid for your collaboration with vetted partners.

Expert Institutions
NotedSource has experts from Stanford University
Expert institutions using NotedSource include Oxfort University
Experts from McGill have used NotedSource to share their expertise
University of Chicago experts have used NotedSource
MIT researchers have used NotedSource
Proudly trusted by
Microsoft uses NotedSource for academic partnerships
Johnson & Johnson academic research projects on NotedSource
ProQuest (Clarivate) uses NotedSource as their industry academia platform
Slamom consulting engages academics for research collaboration on NotedSource
Omnicom and OMG find academics on notedsource
Phoenix Tailings finds academic collaborations on NotedSource
Unilever research project have used NotedSource to engage academic experts

Connect with researchers and scientists like Marina Baretti on NotedSource to help your company with innovation, research, R&D, L&D, and more.